| Literature DB >> 23438846 |
M J Molina-Garrido, C Guillen-Ponce, A Mora-Rufete1.
Abstract
Trastuzumab or lapatinib treatment with chemotherapy or hormonotherapy are the gold standard treatments for human epidermal growth factor receptor 2 (HER2)-positive breast cancer (early breast cancer or metastatic breast cancer). Older patients have been largely underrepresented in clinical trials, and few data on trastuzumab or lapatinib efficacy and toxicity have been reported for this subgroup. This article has reviewed the main articles that have analyzed these items.Entities:
Mesh:
Substances:
Year: 2014 PMID: 23438846 DOI: 10.2174/18715206113139990087
Source DB: PubMed Journal: Anticancer Agents Med Chem ISSN: 1871-5206 Impact factor: 2.505